<DOC>
	<DOCNO>NCT01923545</DOCNO>
	<brief_summary>This study examine dose DA-3031 ( PEG-G-CSF ) similar efficacy safety compare daily G-CSF chemotherapy-induced neutropenia .</brief_summary>
	<brief_title>Phase II Study DA-3031 ( PEG-G-CSF ) Chemotherapy-induced Neutropenia</brief_title>
	<detailed_description>Eligible subject randomly assign receive once-per-cycle DA-3031 ( PEG-G-CSF ) daily G-CSF ( 10 day ) . This study conduct 1 cycle chemotherapy .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Diagnosis stage II III breast cancer 2 . Age : ≥18 , ≤70 3 . TAC regimen adjuvant therapy 4 . ANC≥1,500/mm3 , Platelet≥100,000/mm3 , ECOG : 0 1 5 . Creatinine &lt; 1.5 x ULN 6 . Total bilirubin/AST/ALT &lt; 1.5 x ULN , ALP &lt; 2.5 x ULN 7 . Have give write , inform consent 1 . Received investigational drug within 30 day inform consent date 2 . Received systemic antibiotic within 72 hour chemotherapy study Radiation therapy within 4 week inform consent date 3 . Infective symptom chemotherapy study 4 . Pregnant lactate woman 5 . Prior bone marrow stem cell transplantation 6 . Other malignancy history within 5 year 7 . HIV positive 8 . Prior exposure pegfilgrastim filgrastim colonystimulating factor within 6 week inform consent date 9 . Prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PEG-G-CSF</keyword>
</DOC>